...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

Free
Discussion Forum: Zenith Epigenetics
Message Title
Rating
Author / Date
3
Jan 13, 2021 03:30PM
3
Jan 13, 2021 02:17PM
2
Jan 13, 2021 12:53PM
3
Jan 12, 2021 12:10PM
1
Jan 12, 2021 11:57AM

Jan 12, 2021 11:47AM
1
Jan 12, 2021 11:25AM

Jan 12, 2021 10:38AM
1
Jan 12, 2021 09:22AM
1
Jan 12, 2021 08:27AM